Brief: Ionis Pharmaceuticals Q4 Revenue USD 227 Million Vs. IBES Estimate USD 137.6 Million
19/02/2025 12:00
Feb 19 (Reuters) - Ionis Pharmaceuticals Q4 adjusted operating income USD -74 million vs. IBES estimate USD -176.5 million. * Q4 adjusted operating expenses USD 301 million * Q4 operating income USD -110 million * Q4 operating expenses USD 337 million
Recent news on Ionis Pharmaceuticals
See all newsAnalysis: US prices for new drugs fell in 2025 as fewer costly gene therapies were launched
Brief: Ionis Announces License Agreement With Recordati For Zilganersen In Alexander Disease (Axd) In All Countries Outside The U.S.
Brief: Ionis Pharmaceuticals Says FDA Approved Tryngolza For Severe Hypertriglyceridemia
Brief: FDA Approves Treatment To Reduce Risk Of Acute Pancreatitis In Adults With Severe Hypertriglyceridemia
Brief: Ionis Announces Appointment Of Ludwig Hantson, Ph.D. To Board Of Directors